Some of the authors of the article cited above respond:
To the Editor: We thank Dr. Diamandis for his comments and wish to comment on some of the issues that he raised.
First, we want to clarify that it was not the intention of the original discovery paper (1 ) or of the recent validation paper (2 ) to determine the suitability of "this [SELDI] technology for cancer diagnostics". We used surface-enhanced laser desorption/ ionization (SELDI) technology for biomarker discovery and validation.
We do not disagree with Dr. Diamandis' statement and prediction that candidate biomarkers discovered in serum or plasma by SELDI (and by many other high-throughput proteomics profiling technologies) tend to be high-abundance proteins. We believe, however, that this situation reflects not only the low sensitivity of the current mass spectrometers and other detection technologies, but also the lack of sample preparation (depletion, fractionation) technologies that are applicable for highthroughput analysis with high reproducibility (low CV in both mass accuracy and relative protein expression measurement).
The letter by Dr. Diamandis did not provide any actual data to discount the findings in our 2 papers; the questions he raised centered on the more general issues of whether such abundant proteins can truly be disease-associated biomarkers and whether they can be clinically relevant.
Proteolytic processing of peptides in circulation is a well-known phenomenon, and many of the protein fragments are from abundant proteins that are less likely to be directly secreted from the actual tumor sites. It is also possible, however, that cancer cells and/or the host immune system may produce proteases and other enzymes that are tumor specific and may produce specific fragmentation and cleavage of common proteins, including abundant proteins. An increasing body of evidence, from our own group (3, 4 ) and from others (5, 6 ) , supports such possibilities. The fact that many known serum/plasma biomarkers are abundant proteins or their derivatives could be caused by limitations of the current technology. Alternatively, such biomarkers could be the "amplified" signal of a disease process that otherwise might not be easily detected at an early stage. A tumor biomarker is evaluated by its relevance to the disease; it is not a prerequisite for it to be a direct product of the tumor.
Cancers are heterogeneous diseases with multiple subphenotypes, each following a distinct pathway. With possibly a few exceptions, it is unlikely that a single marker will provide acceptable diagnostic sensitivity and specificity for any of these complex diseases. It is our firm belief that multiple biomarkers, each with clinically verifiable relevance to the disease, combined through statistically sound approaches will offer better diagnostic performance than any individual marker. It is possible that some biomarkers, such as BC2 and BC3, may not be super performers on their own, but provide value in combination with others.
Pretreatment of Serum with Penicillamine: Effects on Capillary Electrophoresis Patterns and on Immunonephelometric Measurement of Immunoglobulins
To the Editor: Capillary zone electrophoresis (CZE) performed on "clinical" analyzers effectively detects monoclonal components (MCs) (1-4 ) in human serum. Some small MCs (5 ), and a few large IgM MCs, escape CZE detection, but the latter are detected in the same assay after pretreatment of serum with thiol reagents (6 -8 ) . We investigated the effects of pretreatment with penicillamine (PA) on the CZE pattern and on measurements of immunoglobulins (IgA, IgG, and IgM) in a variety of sera.
We No PA-induced modification of the CZE pattern was apparent visually in samples not containing IgM MCs. On the other hand, two major modifications were revealed in several samples containing an IgM MC: either the MC peak underwent a marked ␥3␤ displacement (without any perceptible change in the size of the MC); or the MC, "silent" in CZE of native sample, became detectable after PA pretreatment.
To evaluate the frequency of these modifications, we arbitrarily split the whole set of 101 sera with IgM MCs into two subsets according to the size of the MC. Of the 77 samples with a "small" IgM MC (Յ10% of total protein), 13 (17%) exhibited marked ␥3␤ displacement and 9 (12%) revealed the presence of a small MC only after PA pretreatment. In these 9 samples, the MC accounted for 3.8 (0.9)% [mean (SD)] of total protein (range, 2.8%-5.1%) and was superimposed on a normal to increased polyclonal ␥-globulin zone. On the basis of the available evidence, these samples were classified as monoclonal gammopathies of uncertain significance (MGUS). Of the 24 samples with a "large" IgM MC (Ͼ10% of total protein), 12 (50%) exhibited peak displacement, but none revealed the presence of the MC only after PA pretreatment. Examples of these modifications are shown in Fig.  1 . No known characteristic of the IgM MC (e.g., type of light chain) was associated with the observed modifications. We saw no cases of either "reverse" (␤3␥) displacement or marked size modification of the MC peak, as reported in one case (6 ) .
To evaluate possible quantitative modifications of the CZE fractions and of the immunoglobulin after PA pretreatment, we computed the differences [(PA-treated) Ϫ (native)] and their means. Significance was assessed by a two-tailed t-test for paired data. The 5 CZE fractions showed minor but significant variations after PA pretreatment. The most significant and constant variation was the shift of ϳ1% of proteins from the ␥ to the ␤ fraction in all sera; as expected, this shift was much more pronounced (ϳ10%) in the samples with ␥3␤ displacement of the IgM MC peak. Variations of IgA were small (from Ϫ0.6 to 0.7 mg/L), reaching weak significance only in the group of samples with IgM MCs without peak displacement. IgG and IgM showed, respectively, a greater decrease (from Ϫ37.5 to Ϫ108 mg/L) and increase (from 21.6 to 301 mg/L) of mean concentrations, with large sample-to-sample variation.
The salient finding of this study was that an IgM MC was seen only after pretreatment with PA in 9 of 204 selected samples. The arguments for and against the practice of performing serum protein electrophoresis to screen for B-cell malignancies have been discussed recently (9 ) . We conclude that re-running of CZEnegative samples after PA pretreatment should be considered if additional clinical or laboratory findings (e.g., urine protein electrophoresis and serum immunoglobulin) point In comparing serial measurement results from the same patient, PA-induced modifications of quantitative data should also be considered. 
Ilenia

Use of Serum on Guthrie Cards in Screening for Congenital Disorders of Glycosylation
To the Editor: Serum transferrin (Tf) isoform profiling by isoelectric focusing (IEF) (1 ) is the preferred procedure to screen for congenital disorders of glycosylation (CDG). HPLC (2 ) and capillary electrophoresis (CE) (3 ) are recently introduced techniques that offer mainly the advantage of automation. The analyses are usually performed in specialized laboratories, and serum samples are sent primarily via courier. Stibler and Cederberg (4 ) showed that blood samples spotted on Guthrie cards could be used instead of serum for investigating carbohydrate-deficient Tf. We had the same experience with Guthrie cards sent for Tf isoform profiling. In fact, a substantial proportion of the samples we have investigated (886 of 9654 samples) were transported this way (our unpublished data).
Tf obtained by extraction from Guthrie cards may show on IEF an isoform profile that corresponds to a known CDG pattern (Fig. 1A, lane 2) . The Tf profile on CE is unusable because of the high degree of hemolysis. However, when the Tf concentration in serum is low (Fig. 1A, lane  3) or when only a small amount of blood has been spotted on the Guthrie card, the Tf bands are mostly too faint to exclude a CDG. This is particularly true for type II CDG (CDG-II) profiles because of the smaller increases in asialo-and monosialoTf. Increasing the amount of sample on the agarose gel is not useful because it increases the background (Fig. 1A, lane 4) .
We obtained 393 abnormal IEF profiles suggestive of CDG among 8768 serum samples (4.5%) and 9 abnormal profiles among 886 blood samples on Guthrie cards (1%; our unpublished data), and investigated whether the application of serum instead of whole blood could combine the usefulness of Guthrie cards with the accuracy of serum analysis.
The protein concentration in each sample was determined by the BIO-RAD assay. IEF and CE analyses of sialo-Tf were performed as described previously (3 ) .
Sera spotted on the Guthrie cards originated from serum pools that were obtained from control samples (permanently stored at Ϫ20°C) and from patients with CDG-I or CDG-II. After 250 L of serum was spotted on a Guthrie card, the card was enclosed in a plastic bag and sealed after air removal. After 2 weeks at room temperature or Ϫ20°C, spots were cut and snipped and dispersed in a volume (in microliters) of physiologic saline-2 mL/L Triton X-100 equal to 10 times the weight of the paper (in milligrams); this surfactant solution is used for homogenization of intestinal mucosal biopsies (5 ). Protein was extracted overnight at room temperature under constant stirring. After centrifugation for 10 min at 13 000g, the supernatant was lyophilized and the residue was dissolved in 50 L of physiologic saline. Tf isoform profiling was performed by IEF and by CE.
The mean (SD) protein recovery with this extraction procedure was 10 (0.3)% (n ϭ 10). Thus, ϳ300 L of serum should be applied on the Guthrie cards for IEF and CE analysis to provide the equivalent to 30 L of serum in the extract. As this would correspond to at least 0.5 mL of blood, it is clear that in many cases the amount applied on Guthrie cards is too low for Tf analysis.
The intensities of the Tf isoforms in the samples stored at Ϫ20°C were slightly higher than the intensities in samples stored at room temperature (Fig. 1B) . The CE profiles (Fig. 1C) corresponded to the expected Tf patterns for the same control (trace 1), CDG-I (trace 2), and CDG-II (trace 3) sera on the Guthrie cards after 2 weeks of storage at Ϫ20°C.
We have observed neither analyti-
